Severe Asthma Outcomes Linked to Distal Airway Dysfunction

Small Airways Disease is increasingly recognized as a critical clinical trait that influences the management of severe asthma. While biologic therapies have revolutionized care for many patients, a significant subset continues to experience frequent exacerbations. Recent clinical evidence suggests that the presence of dysfunction in the peripheral airways, those less than 2 mm in diameter, significantly predicts a poor response to these advanced treatments. Understanding this relationship allows physicians to better phenotype patients and tailor management strategies accordingly.

Understanding the Impact of Small Airways Disease on Biologic Efficacy

A recent retrospective cohort study involving 156 adult patients investigated the prevalence of Small Airways Disease and its association with therapeutic outcomes over 12 months. The research cohort included patients treated with omalizumab, benralizumab, mepolizumab, or dupilumab. At baseline, nearly 44% of the participants exhibited SAD. Notably, the study found that SAD was significantly more prevalent among non-responders than those who achieved clinical success. Consequently, the researchers identified SAD as an independent predictor of treatment failure, with affected patients having over three times the odds of remaining uncontrolled despite biologic intervention.

Role of Oscillometry in Clinical Practice

Traditional spirometry remains the standard for monitoring lung function, yet it often lacks the sensitivity required to detect changes in the distal lungs. In contrast, the Forced Oscillation Technique (FOT), or oscillometry, provides a detailed assessment of peripheral airway resistance and reactance. Specifically, the study highlighted that an abnormality in the X5 parameter, which reflects peripheral lung compliance, was a potent predictor of non-response. Therefore, clinicians should consider integrating oscillometry into their diagnostic toolkit to identify Small Airways Disease more accurately than through spirometry alone.

Improving Treatment Response with Biologics

Identifying Small Airways Disease at the start of therapy helps clinicians establish realistic expectations for biologic success. Furthermore, this knowledge may prompt a search for additional interventions that specifically target the distal airways. Because SAD increases the risk of frequent exacerbations, monitoring peripheral lung function becomes essential for comprehensive asthma care. Ultimately, addressing these distal physiological defects through a multifaceted approach may lead to improved long-term outcomes for patients with the most severe forms of the disease.

Frequently Asked Questions

What is the prevalence of Small Airways Disease in severe asthma patients?

In this clinical cohort, approximately 44% of patients with severe asthma were diagnosed with Small Airways Disease at baseline. However, some real-world studies suggest that the prevalence may be higher when using advanced diagnostic tools like oscillometry.

Why is oscillometry preferred over spirometry for assessing SAD?

Oscillometry is an effort-independent test that is highly sensitive to the mechanics of the peripheral lungs. It can detect resistance and reactance abnormalities that spirometry often misses, making it a superior tool for evaluating distal airway function.

Can biologics still be effective if Small Airways Disease is present?

While SAD is a predictor of a lower response rate, many patients still derive benefits from biologic therapy. However, those with baseline SAD are at a higher risk of remaining non-responders and may require closer monitoring or adjunctive treatment strategies.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Allegrini C et al. Small Airways Disease Adversely Impacts the Response to Biologic Therapies in Severe Asthma. Pulm Ther. 2026 Feb 28. doi: 10.1007/s41030-026-00353-2. PMID: 41762423.


2. Chan R, Lipworth BJ. Impact of Biologic Therapy on the Small Airways Asthma Phenotype. Lung. 2022 Oct;200(5):543-556.


3. Berti A, et al. Small airway dysfunction in asthma: a real life study. Allergy. 2020;75(4):856-864.